QMSR readiness and gap assessment
Assess the current system against the FDA’s Quality Management System Regulation, ISO 13485 expectations, and the company’s real responsibilities, then prioritize the changes that will improve readiness.
21 CFR 820 CONSULTING
21 CFR 820 Consulting for Medical Devices
Build a quality system that supports your device, your team, and the decisions that need to stand up to review.
Discuss your quality system →QUALITY THAT WORKS IN PRACTICE
Make the system useful before it is tested.
A medical-device quality system is not simply a set of procedures to have on hand for an inspection. It is the operating structure behind design decisions, supplier relationships, production controls, complaints, changes, corrective actions, and the evidence a company relies on when questions arise. When those pieces were built at different times or owned by different functions, the gaps usually appear when the organization is under pressure.
Qualira helps teams turn 21 CFR 820 and QMSR expectations into a practical system for the way their device program actually works. The focus is on the decisions, controls, and records that matter to the product and the business, so quality work supports progress instead of becoming a disconnected paperwork exercise.
WHERE QUALIRA HELPS
Senior support for the controls behind a credible device program.
Design and risk controls
Connect design planning, user needs, inputs, verification, validation, risk management, and change control so the records support the device story from development through release.
Supplier and production quality
Strengthen supplier qualification, purchasing controls, incoming acceptance, production records, and oversight routines around the risks that could affect the finished device.
CAPA, complaints, and inspection readiness
Clarify how issues are investigated, corrected, documented, trended, and escalated, so the organization can show that quality signals lead to effective action.
FROM REQUIREMENT TO DAILY PRACTICE
Quality controls should make better decisions easier.
Regulatory requirements set an important baseline, but a quality system earns its value in daily use. It should help teams know who owns a decision, what evidence is needed, how a change should be assessed, when a supplier needs more oversight, and what to do when a complaint or nonconformance signals a deeper issue. A system that only works when someone is preparing for an audit leaves the business exposed at exactly the wrong moments.
Qualira starts with the device, the product lifecycle, and the pressure points facing the team. A company preparing for its first FDA inspection may need to test whether procedures are truly reflected in records and behavior. A growing manufacturer may need clearer supplier controls or a more dependable CAPA process. A mature organization may need to integrate the QMSR transition without disrupting controls that already work.
The right answer is rarely to rewrite everything. Often, the highest-value work is identifying which gaps could undermine the program, resolving conflicting practices, assigning durable ownership, and building a realistic sequence for the remaining improvements. That keeps the quality system proportionate to the organization while making it easier to defend.
THE QUESTIONS THAT SHAPE THE WORK
Find the quality decisions that create the most downstream confidence.
Quality systems become fragile when people cannot see how the controls connect to the device and its risks. Procedures may exist, but records do not demonstrate consistent use. An issue may be corrected locally without asking whether the same cause exists elsewhere. A supplier may be approved once and then receive little meaningful oversight. The practical work is finding where the system has lost that connection and restoring it before an audit, submission, or market event makes the gap more expensive.
Scope and ownership
What activities, sites, suppliers, software, and products fall within the quality system, and who has the authority to make the relevant decisions? Clear scope and ownership keep important controls from becoming assumptions between departments.
Evidence that matches the process
Training records, design records, investigations, supplier files, change assessments, and management reviews should show how the organization works in reality. Qualira helps teams look for the points where written procedures and operating evidence have drifted apart.
Issues that lead to durable correction
Complaints, nonconformances, audit findings, and production signals should lead to an investigation that is proportionate to the risk. A useful CAPA process identifies the cause, checks the reach of the issue, verifies the action, and captures learning before the same problem returns in a new form.
Readiness that survives the review date
Inspection readiness is not a folder prepared in the final week. It comes from management routines, trained owners, retrievable records, and a team that understands how its controls support the product. This makes an inspection less disruptive and strengthens the program well after it ends.
PRACTICAL QUALITY LEADERSHIP
Bring a senior view to the controls that carry the most risk.
Qualira’s quality, regulatory, clinical, and technical experience allows the team to look beyond a single procedure or audit observation. The question is how a quality decision affects the product, its evidence, the regulatory case, and the organization’s ability to respond as the device changes.
That perspective is useful for a targeted gap assessment, an inspection-readiness review, remediation after an observation, support during a QMSR transition, or a broader quality-system implementation. The goal is a practical plan that your team can own and maintain, not a generic system that becomes difficult to operate once the engagement ends.
View client outcomes →A USEFUL FIRST CONVERSATION
Bring the quality question that is making the program harder to manage.
Which quality-system controls need attention before our next FDA inspection, certification audit, submission, or launch?
Where do our procedures, records, and daily practices no longer tell the same story?
How should we prioritize QMSR transition work without weakening what already functions well?
Do we need a targeted assessment, remediation support, or experienced quality leadership across the program?
FREQUENTLY ASKED QUESTIONS
Frequently asked questions
What does a 21 CFR 820 consultant help with?
A consultant can help a medical-device team identify which quality-system decisions, records, and controls need attention, then turn that assessment into a practical plan for the device, suppliers, and stage of growth.
Does 21 CFR Part 820 still apply after the QMSR transition?
The FDA’s Quality Management System Regulation took effect on February 2, 2026 and incorporates ISO 13485:2016 by reference with FDA-specific requirements. Teams still need a quality system that supports their device and the way they operate.
Can Qualira help before an FDA inspection or certification audit?
Yes. Inspection and audit readiness is stronger when it starts with the underlying system rather than a last-minute document sweep. Qualira can help assess the records, ownership, training, CAPA, design controls, supplier controls, and management routines that need to hold up under review.
Can you support an existing quality team?
Yes. Qualira can add senior perspective to an internal quality group, a defined remediation effort, a transition plan, or a readiness review. The goal is to strengthen the work already underway and leave the organization with controls it can operate.
TALK WITH QUALIRA